Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash & Current Investments (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Cash & Current Investments readings, the most recent being $77.9 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 110.02% to $77.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $77.9 million, a 110.02% increase, with the full-year FY2025 number at $77.9 million, up 110.02% from a year prior.
  • Cash & Current Investments hit $77.9 million in Q4 2025 for Aligos Therapeutics, up from $42.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $242.2 million in Q3 2021 to a low of $24.4 million in Q1 2024.
  • Median Cash & Current Investments over the past 5 years was $110.3 million (2022), compared with a mean of $121.6 million.
  • Biggest five-year swings in Cash & Current Investments: plummeted 76.46% in 2024 and later soared 728.98% in 2025.
  • Aligos Therapeutics' Cash & Current Investments stood at $187.0 million in 2021, then tumbled by 56.44% to $81.4 million in 2022, then skyrocketed by 66.74% to $135.8 million in 2023, then plummeted by 72.68% to $37.1 million in 2024, then soared by 110.02% to $77.9 million in 2025.
  • The last three reported values for Cash & Current Investments were $77.9 million (Q4 2025), $42.1 million (Q3 2025), and $123.0 million (Q2 2025) per Business Quant data.